LatticeMLS
Menu

Module HEME-27 · Version 1.0

Myeloproliferative Neoplasms: Integrated Pattern Evaluation

Recognize sustained count and morphologic patterns that support a bounded MPN workup, then integrate molecular and marrow evidence without overcalling an entity.

Your next section

Start section 1

Read without an account. Sign in to save.

Who this module is for

Advanced medical laboratory scientists and hematology laboratory staff who review CBC patterns, peripheral smears, and molecular test results.

Learning objectives

  • Differentiate erythrocytosis, thrombocytosis, neutrophilia, basophilia, and leukoerythroblastosis patterns.
  • Recognize marrow and film clues for PV, ET, PMF, and related entities.
  • Explain the roles and limits of JAK2, CALR, MPL, BCR::ABL1, and related molecular testing.

How completion works

Mark every required section done and answer every knowledge check in those sections correctly. The final save completes the module automatically.

Sources

10 sources

  1. 1. WHO Classification of Tumours Editorial Board. Haematolymphoid Tumours, WHO Classification of Tumours, 5th ed, Vol 11. IARC, 2024.

    Source note · consensus standard

  2. 2. Gianelli U, Thiele J, Orazi A, et al. International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms. Virchows Archiv. 2023;482:53-68. doi:10.1007/s00428-022-03480-8.

    Source note · peer-reviewed literature

  3. 3. Mithoowani S, Laureano M, Crowther MA, Hillis CM. Investigation and management of erythrocytosis. CMAJ. 2020;192:E913-E918.

    Source note · peer-reviewed literature

  4. 4. Bleeker JS, Hogan WJ. Thrombocytosis: Diagnostic Evaluation, Thrombotic Risk Stratification, and Risk-Based Management Strategies. Thrombosis. 2011;2011:536062.

    Source note · peer-reviewed literature

  5. 5. Gong JZ, et al. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms. Journal of Molecular Diagnostics. 2013;15:733-744.

    Source note · professional society guidance

  6. 6. Association for Molecular Pathology. Molecular in My Pocket: Myeloproliferative Neoplasms, revised July 2025.

    Source note · professional society guidance

  7. 7. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128-1132.

    Source note · consensus standard

  8. 8. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias. Blood. 2022;140:1200-1228.

    Source note · peer-reviewed literature

  9. 9. Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057-1069.

    Source note · professional society guidance

  10. 10. Centers for Medicare & Medicaid Services. 42 CFR Part 493, Laboratory Requirements, current eCFR.

    Source note · federal regulation